Leukemia, Plasma Cell - 19 Studies Found
| Completed |
: Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia : Primary Plasma Cell Leukemia : 2012-03-03 : Drug: Lenalidomide, dexamethasone Enrolled patients receiv |
| Completed |
: Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia :
: 2011-03-29 :
|
| Terminated |
: Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma :
: 2012-08-03 :
|
| Completed |
: Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 : Multiple Myeloma : 2016-08-04 : Drug: PAD-VCD 12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) |
| Completed |
: Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants :
: 2006-03-23 :
|
| Completed |
: A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma : Multiple Myeloma, Plasma Cell Leukemia : 2010-11-24 :
|
| Recruiting |
: Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma :
: 2015-07-20 :
|
| Withdrawn |
: Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma :
: 2014-12-09 : Drug: Bendamustine Given IV Other Names: |
| Completed |
: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma :
: 2009-01-09 :
|
| Terminated |
: Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen :
: 2008-01-22 :
|